pentobarbital will decrease the extent or outcome of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic effect of elbasvir/grazoprevir may be decreased if coadministered with robust CYP3A inducers and is particularly thus contraindicated.pentobarbital will minimize the level or influence